Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin.

BACKGROUND AND PURPOSE Dynamic, contrast-enhanced MR imaging has allowed quantitative assessment of cerebral blood volume (CBV) in brain tumors. The purpose of our study was to compare postcontrast T1-weighted imaging with dynamic, contrast-enhanced T2*-weighted echo-planar imaging in the evaluation of the response of recurrent malignant gliomas to thalidomide and carboplatin. METHODS Serial MR imaging was performed in 18 consecutive patients with recurrent malignant gliomas receiving both thalidomide and carboplatin for 12-month periods. Six patients undergoing carboplatin therapy alone were chosen as control subjects. Conventional postcontrast T1-weighted images were compared with relative CBV (rCBV) maps calculated on a pixel-by-pixel basis from dynamic echo-planar imaging data. Tumor progression was evaluated clinically using established criteria for malignant gliomas. Studies were performed at 2- to 3-month intervals, and imaging and clinical findings were compared. RESULTS Tumor response to treatment, based on clinical findings, did not correlate well with conventional imaging findings. The rCBV values decreased significantly in all patients between the start of therapy and the first follow-up in the study group, but not in the control group. The difference in rCBV values between the clinically stable and the progressive group at 12-month follow-up was statistically significant, with the progressive group having higher values. CONCLUSION Dynamic, contrast-enhanced MR imaging is a valuable adjunct to conventional imaging in assessing tumor activity during antiangiogenic therapy, and correlates better than conventional studies with clinical status and response to therapy.

[1]  H. Scherer,et al.  THE FORMS OF GROWTH IN GLIOMAS AND THEIR PRACTICAL SIGNIFICANCE , 1940 .

[2]  W. Mcbride,et al.  Thalidomide and Congenital Abnormalities , 1961 .

[3]  G. Mellin,et al.  The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies. , 1962, The New England journal of medicine.

[4]  J. Sheskin.  Further observation with thalidomide in lepra reactions. , 1965, Leprosy review.

[5]  S. Brem.  The role of vascular proliferation in the growth of brain tumors. , 1976, Clinical neurosurgery.

[6]  J. Sheskin.  The Treatment of Lepra Reaction In Lepromatous Leprosy , 1980, International journal of dermatology.

[7]  M. Sage.  Blood-brain barrier: phenomenon of increasing importance to the imaging clinician. , 1982, AJR. American journal of roentgenology.

[8]  Sage Mr.  Blood-brain barrier: phenomenon of increasing importance to the imaging clinician. , 1982, AJR. American journal of roentgenology.

[9]  T. Nagashima,et al.  [A review of cell kinetic studies on brain tumors with special reference to anti-bromodeoxyuridine monoclonal antibody method]. , 1984, No shinkei geka. Neurological surgery.

[10]  C. Claussen,et al.  Brain tumors: MR imaging with gadolinium-DTPA. , 1985, Radiology.

[11]  S. Green,et al.  Glioblastoma multiforme and anaplastic astrocytoma pathologic criteria and prognostic implications , 1985, Cancer.

[12]  P. Burger,et al.  Malignant astrocytic neoplasms: classification, pathologic anatomy, and response to treatment. , 1986, Seminars in oncology.

[13]  William H. Press,et al.  Numerical Recipes in FORTRAN - The Art of Scientific Computing, 2nd Edition , 1987 .

[14]  W. Lenz.  A short history of thalidomide embryopathy. , 1988, Teratology.

[15]  B. Drayer,et al.  Gd-DTPA-enhanced MR imaging in pediatric patients after brain tumor resection. , 1988, Radiology.

[16]  W. J. Oakes,et al.  Criteria for termination of phase II chemotherapy for patients with progressive or recurrent brain tumor , 1989, Neurology.

[17]  F. A. Seiler,et al.  Numerical Recipes in C: The Art of Scientific Computing , 1989 .

[18]  B. Rosen,et al.  Perfusion imaging with NMR contrast agents , 1990, Magnetic resonance in medicine.

[19]  R R Edelman,et al.  Cerebral blood flow: assessment with dynamic contrast-enhanced T2*-weighted MR imaging at 1.5 T. , 1990, Radiology.

[20]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  S. Naber,et al.  Expression of angiogenic growth factor genes in primary human astrocytomas may contribute to their growth and progression. , 1991, Cancer research.

[22]  T. Hoshino.  Cell kinetics of glial tumors. , 1992, Revue neurologique.

[23]  B. Jeremic,et al.  Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: a phase II study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Donald S. Williams,et al.  Perfusion imaging , 1992, Magnetic resonance in medicine.

[25]  K Sartor,et al.  Extirpation of glioblastomas: MR and CT follow-up of residual tumor and regrowth patterns. , 1993, AJNR. American journal of neuroradiology.

[26]  A. Nobre,et al.  Qualitative mapping of cerebral blood flow and functional localization with echo-planar MR imaging and signal targeting with alternating radio frequency. , 1994, Radiology.

[27]  E F Halpern,et al.  Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. , 1994, Radiology.

[28]  R. D'Amato,et al.  Thalidomide is an inhibitor of angiogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. Griffin,et al.  Thalidomide revisited. , 1994, Adverse drug reactions and toxicological reviews.

[30]  Susan M. Chang,et al.  Chemotherapy for gliomas , 1995, Current opinion in oncology.

[31]  B. Scheithauer,et al.  Histopathology, classification, and grading of gliomas , 1995, Glia.

[32]  J. Murray,et al.  A mathematical model of glioma growth: the effect of chemotherapy on spatio‐temporal growth , 1995, Cell proliferation.

[33]  S. Wnendt,et al.  Immunomodulation by thalidomide: systematic review of the literature and of unpublished observations. , 1995, Journal of inflammation.

[34]  H. Fine.  Novel biologic therapies for malignant gliomas. Antiangiogenesis, immunotherapy, and gene therapy. , 1995, Neurologic clinics.

[35]  H. Hochster,et al.  Improved long term survival after intracavitary interleukin‐2 and lymphokine‐activated killer cells for adults with recurrent malignant glioma , 1995, Cancer.

[36]  Seong-Gi Kim.  Quantification of relative cerebral blood flow change by flow‐sensitive alternating inversion recovery (FAIR) technique: Application to functional mapping , 1995, Magnetic resonance in medicine.

[37]  J. Folkman,et al.  Angiostatin induces and sustains dormancy of human primary tumors in mice , 1996, Nature Medicine.

[38]  M. Castillo,et al.  Clinical applications of proton MR spectroscopy. , 1996, AJNR. American journal of neuroradiology.

[39]  B. Rosen,et al.  High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part II: Experimental comparison and preliminary results , 1996, Magnetic resonance in medicine.

[40]  W. Reddick,et al.  Clinical value of proton magnetic resonance spectroscopy for differentiating recurrent or residual brain tumor from delayed cerebral necrosis. , 1996, International journal of radiation oncology, biology, physics.

[41]  R. Dewar,et al.  The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[42]  M. Hayes,et al.  The effect of thalidomide on experimental tumors and metastases , 1996, Anti-cancer drugs.

[43]  Gilla Kaplan,et al.  Selection of Novel Analogs of Thalidomide with Enhanced Tumor Necrosis Factor α Inhibitory Activity , 1996, Molecular medicine.

[44]  M. Castillo,et al.  MR of recurrent high-grade astrocytomas after intralesional immunotherapy. , 1996, AJNR. American journal of neuroradiology.

[45]  C. Hesdorffer,et al.  Thiotepa and etoposide treatment of recurrent malignant gliomas: phase I study , 1997, Cancer Chemotherapy and Pharmacology.

[46]  K. Krabbe,et al.  MR diffusion imaging of human intracranial tumours , 1997, Neuroradiology.

[47]  J. Stears,et al.  Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2 , 1997, Cancer Immunology, Immunotherapy.

[48]  Susan M. Chang,et al.  Serial proton magnetic resonance spectroscopy imaging of glioblastoma multiforme after brachytherapy. , 1997, Journal of neurosurgery.

[49]  J. Folkman,et al.  Suppression of tumor growth with recombinant murine angiostatin. , 1997, Biochemical and biophysical research communications.

[50]  A. Nirenberg,et al.  Carboplatin chemotherapy before irradiation in newly diagnosed glioblastoma multiforme. , 1998, American journal of clinical oncology.

[51]  M A Goldberg,et al.  Cerebral toxoplasmosis and lymphoma in AIDS: perfusion MR imaging experience in 13 patients. , 1998, Radiology.

[52]  M. Castillo,et al.  Proton MR spectroscopy in neoplastic and non-neoplastic brain disorders. , 1998, Magnetic resonance imaging clinics of North America.

[53]  Toshinori Hirai,et al.  Usefulness of diffusion‐weighted MRI with echo‐planar technique in the evaluation of cellularity in gliomas , 1999, Journal of magnetic resonance imaging : JMRI.

[54]  G Johnson,et al.  Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. , 1999, Radiology.